Current Breast Cancer Reports is a vital academic journal published by Springer that focuses on the latest research and advancements in the field of breast cancer. With its ISSN 1943-4588 and E-ISSN 1943-4596, this journal serves as an essential resource for oncologists, researchers, and healthcare professionals dedicated to improving diagnosis and treatment strategies for breast cancer. Spanning from 2009 to 2024, it provides a platform for high-quality, peer-reviewed articles that encompass a range of topics, including molecular biology, clinical trials, and innovative therapeutic approaches. Although it is currently classified in the Q3 category in Oncology and is positioned in the 29th percentile, the journal remains committed to elevating its academic impact and contributing meaningfully to the ongoing fight against breast cancer. As it seeks to disseminate critical findings and foster collaboration within the scientific community, Current Breast Cancer Reports is poised to be an indispensable tool for anyone keen on advancing the field.

Pain and Therapy is a prestigious, peer-reviewed journal published by SPRINGER INTERNATIONAL PUBLISHING AG that has been a beacon of research in the field of pain management and neurology since its inception in 2012. With an ISSN of 2193-8237 and an E-ISSN of 2193-651X, this open access journal facilitates the dissemination of high-quality research to a global audience. Recognized within the top Q1 quartile for Anesthesiology and Pain Medicine, and the Q2 category for Clinical Neurology, it ranks impressively within the Scopus indexing, positioned at #20/136 in its primary category, demonstrating an 85th percentile standing. The journal's commitment to open access enhances its impact, allowing researchers, clinicians, and students to explore and contribute to critical developments in pain therapy and management. The convergence of cutting-edge research and innovative therapeutic strategies makes Pain and Therapy an essential resource for anyone dedicated to advancing knowledge in this vital field.

Expert Review of Clinical Immunology is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, dedicated to advancing the field of immunology, with a particular focus on clinical applications and therapeutic developments. With an ISSN of 1744-666X and an E-ISSN of 1744-8409, this journal has made a significant impact in the scientific community, evidenced by its Q2 ranking in both Immunology and Allergy for 2023, as well as solid placements in Scopus ranks (73/233 and 87/236 in their respective categories). Operating from the United Kingdom, the journal publishes comprehensive reviews designed to keep researchers, clinicians, and students updated on cutting-edge advancements and trends in immunology. Although it is not an open-access journal, its high impact factor and rigorous editorial standards reinforce its relevance and importance in providing high-quality, evidence-based information. As we progress towards 2024, Expert Review of Clinical Immunology remains a vital resource for anyone involved in the immunological sciences, facilitating knowledge exchange and fostering innovative research within this critical area of medicine.

Journal of Drugs in Dermatology, an esteemed publication in the field of dermatology, serves as a vital resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge and practices in skin-related therapies and treatments. Established in 2002 and published in the United States, this journal focuses on a wide range of topics pertinent to dermatological pharmacology and therapeutics, reflecting contemporary scientific advancements and innovative approaches to patient care. With a strong presence in Scopus rankings, situating it at rank #73 within the dermatology category, and achieving a commendable Q2 quartile classification in both dermatology and general medicine categories, the journal is committed to enhancing understanding of drug efficacy and safety in dermatological conditions. While the journal maintains a traditional access model, its impact factor underscores its significance in the research community, supporting the ongoing dialogue between academia and clinical practice. We invite professionals and students alike to explore the latest findings and contribute to the progressive discourse on dermatological treatments through this important publication.

Future Oncology is a premier peer-reviewed journal published by FUTURE MEDICINE LTD, dedicated to advancing research and innovation within the field of oncology. Established in 2005 and set to continue through 2024, this journal serves as an essential resource for researchers, healthcare professionals, and students engaged in cancer studies. With its emphasis on groundbreaking findings and multidisciplinary approaches, Future Oncology holds an esteemed reputation, reflected in its 2023 category quartiles ranking it in Q2 for Cancer Research and Q1 for Medicine (miscellaneous). The journal is indexed in Scopus, showcasing its rigorous content, with rankings in the 63rd percentile for Oncology and the 46th percentile for Cancer Research. Although it does not operate on an open-access model, its commitment to disseminating cutting-edge findings makes it an invaluable asset for those seeking to stay at the forefront of oncology research.Future Oncology strives to bridge the gap between laboratory and clinical research, fostering collaboration and appreciation for the complexities of cancer treatment.

Dermatology Research and Practice is a premier open access journal published by HINDAWI LTD, dedicated to advancing the field of dermatology since its establishment in 2009. With a respectable impact factor and a ranking of #42 out of 142 in the Scopus Medicine - Dermatology category, the journal stands in the 70th percentile, reflecting its influence and relevance in contemporary dermatological research. Based in Egypt, it provides a platform for groundbreaking studies that shape clinical practice and policy worldwide. The journal covers a wide range of topics within dermatology, including but not limited to clinical research, epidemiology, and patient care, making it an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding and contribute to the field. Emphasizing open access, Dermatology Research and Practice ensures that vital research findings are readily available to the global community, fostering collaboration and innovation in dermatology.

DERMATOLOGY, an esteemed journal published by KARGER, is a vital resource in the field of dermatological research and clinical practice. Established in 1893, with its comprehensive coverage extending to 2024, this journal has earned its place as a leading publication, holding a prestigious Q1 quartile ranking in Dermatology and ranking 15th out of 142 in the Scopus Medicine - Dermatology category, reflecting its 89th percentile standing within the discipline. The journal aims to disseminate innovative research findings, critical reviews, and clinical studies that advance the understanding of skin disorders and their treatments. While primarily available through institutional subscriptions, DERMATOLOGY remains committed to enhancing accessibility and fostering international collaboration among researchers, professionals, and students in the dermatological community. Its rigorous peer-review process guarantees the highest quality of published works, making it an essential reference for those dedicated to advancing dermatological science and improving patient care.

The Hong Kong Journal of Dermatology & Venereology is a vital publication in the field of dermatology, dedicated to advancing research and clinical practice in this specialized area. Published by MEDCOM LTD, this journal has been a resourceful platform for dermatologists, researchers, and students since its inception in 2005, showcasing rigorous original research, comprehensive reviews, and case studies pertinent to both dermatology and venereology. Although currently categorized in Q4 of the dermatology quartiles, it serves as an important voice for the region, contributing to the global dialogue on skin and sexually transmitted diseases. With an ISSN of 1814-7453, the journal aims to bridge gaps in understanding and foster innovations that will lead to better patient care and outcomes. Readers can access its content, while researchers are encouraged to contribute to this growing body of knowledge that plays a critical role in enhancing dermatological practice in Hong Kong and beyond.

Actas Dermo-Sifiliograficas, published by Elsevier España, stands as a pivotal resource in the realms of dermatology, histology, and pathology and forensic medicine. With its ISSN of 0001-7310 and E-ISSN 1578-2190, this esteemed journal has transitioned to an Open Access model since 2020, facilitating broader dissemination of impactful research. Operating from its Madrid headquarters, it has been a vital platform for scholarly exchange since its inception in 1945, continuing through its converged years until 2024. The journal holds a Q3 ranking in dermatology, histology, and pathology and forensic medicine as of 2023, reflecting its relevance in the academic community where it ranks 79th in dermatology and 126th in pathology among its peers. With a commitment to advancing knowledge and practice in its fields, Actas Dermo-Sifiliograficas serves as an essential repository for researchers, professionals, and students seeking to engage with the latest findings and innovative perspectives in skin and disease research.

Psoriasis-Targets and Therapy is a leading open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the knowledge and understanding of psoriasis treatment and management. Launched in 2011, this journal provides a platform for high-quality research that encompasses clinical studies, therapeutic advances, and novel targeted therapies for psoriasis. With a focus on the latest findings and innovative approaches, Psoriasis-Targets and Therapy serves as an essential resource for researchers, healthcare professionals, and students seeking to stay at the forefront of this dynamic field. The journal's commitment to open-access publishing ensures that critical insights and breakthroughs are readily available to the global medical community, fostering collaboration and progress in psoriasis treatment strategies. Researchers are encouraged to submit their findings to contribute to the growing body of knowledge that will ultimately improve patient care and outcomes.